Clinical Trials

The purpose of this study is to compare the usual treatment (enzalutamide) alone to using rucaparib plus the usual treatment. The addition of rucaparib to the usual treatment could make patients live longer, or prevent cancer from growing or spreading for a longer time, or both.

This is a retrospective controlled survey-study to assess the safety of treating migraine with Nerivio during pregnancy and 3 months postpartum. We will compare migraine and pregnancy related health and baby health between women with migraine who treated migraine attacks during pregnancy with Nerivio (Nerivio group), to women with migraine who did not treat migraine attacks during pregnancy with Nerivio (control group). Nerivio group participants will be recruited from Theranica’s user base. Control group participants will be recruited by health care providers, including headache specialists and OBGYNs (study co-investigators). The study is fully electronic, including an e-eligibility questionnaire, an e-ICF, and an e-survey. Participants will be compensated for their time.

Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).

This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer.

The goal of this clinical trial is to determine whether an upfront invasive strategy of TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause death or major aortic complications compared to an upfront conservative strategy of medical therapy with surveillance for deterioration in patients with uncomplicated type B aortic dissection.

The investigational Vascular Covered Stent is a self-expanding, low profile, polytetrafluoroethylene encapsulated nitinol implant. It is deployed from a delivery system that provides controlled stent release.